Stephen J Richards

List of Publications by Year
in descending order

82 papers	6,861 citations	101543 36 h-index	66911 78 g-index
85 all docs	85 docs citations	85 times ranked	5433 citing authors

#	Article	IF	Citations
1	Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood, 2005, 106, 3699-3709.	1.4	652
2	Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine, 2004, 350, 552-559.	27.0	541
3	Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2008, 359, 575-583.	27.0	518
4	Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood, 2011, 117, 6786-6792.	1.4	410
5	Monoclonal B lymphocytes with the characteristics of â€œindolentâ€•chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood, 2002, 100, 635-639.	1.4	305
6	The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells. Cancer Research, 2007, 67, 8444-8449.	0.9	284
7	Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood, 2003, 102, 3587-3591.	1.4	252
8	Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood, 2001, 98, 29-35.	1.4	249
9	Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood, 2002, 100, 2289-2290.	1.4	207
10	Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood, 2005, 106, 2559-2565.	1.4	199
11	Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. Nature Medicine, 2006, 12, 846-851.	30.7	196
12	Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry Part B - Clinical Cytometry, 2010, 78B, 211-230.	1.5	195
13	Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica, 2010, 95, 567-573.	3.5	166
14	Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. British Journal of Haematology, 1997, 97, 46-55.	2.5	165
15	Subtype-specific regulatory network rewiring in acute myeloid leukemia. Nature Genetics, 2019, 51, 151-162.	21.4	140
16	WaldenstrÃ¶m Macroglobulinemia. American Journal of Clinical Pathology, 2001, 116, 420-428.	0.7	137
17	Effect of eculizumab on haemolysisâ€associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 2010, 149, 414-425.	2.5	137
18	Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry, 2000, 42, 223-233.	1.8	132

#	Article	IF	Citations
19	Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 2007, 137, 181-192.	2.5	130
20	The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. British Journal of Haematology, 2010, 149, 446-450.	2.5	122
21	The impact of attaining a minimal disease state after highâ€dose melphalan and autologous transplantation for multiple myeloma. British Journal of Haematology, 2001, 112, 814-819.	2.5	103
22	High-Producer Haplotypes of Tumor Necrosis Factor Alpha and Lymphotoxin Alpha Are Associated With an Increased Risk of Myeloma and Have an Improved Progression-Free Survival After Treatment. Journal of Clinical Oncology, 2000, 18, 2843-2851.	1.6	91
23	The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood, 2000, 96, 3880-3886.	1.4	78
24	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leukemia and Lymphoma, 2013, 54, 472-475.	1.3	66
25	The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. British Journal of Haematology, 1999, 107, 148-153.	2.5	64
26	Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood, 2004, 103, 2027-2031.	1.4	64
27	IMPLICATIONS OF RECENT INSIGHTS INTO THE PATHOPHYSIOLOGY OF PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA. British Journal of Haematology, 2000, 108, 470-479.	2.5	63
28	Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature. Cell Reports, 2015, 12, 821-836.	6.4	63
29	Protection of erythrocytes from human complementâ€“mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood, 2006, 107, 2131-2137.	1.4	49
30	Underâ€recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. British Journal of Haematology, 2012, 158, 409-414.	2.5	48
31	Transient and persistent expansions of large granular lymphocytes (LGL) and NK-associated (NKa) cells: the Yorkshire Leukaemia Group study. British Journal of Haematology, 1993, 83, 504-515.	2.5	43
32	The Incidence and Prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Survival of Patients in Yorkshire.. Blood, 2006, 108, 985-985.	1.4	41
33	The Role of Flow Cytometry in the Diagnosis of Paroxysmal Nocturnal Hemoglobinuria in the Clinical Laboratory. Clinics in Laboratory Medicine, 2007, 27, 577-590.	1.4	40
34	Lymphocyte Subset Analysis and Glycosylphosphatidylinositol Phenotype in Patients With Paroxysmal Nocturnal Hemoglobinuria. Blood, 1998, 92, 1799-1806.	1.4	39
35	Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria. Cytometry Part B - Clinical Cytometry, 2007, 72B, 291-298.	1.5	39
36	A distinct large granular lymphocyte (LGL)/NK-associated (NKa) abnormality characterized by membrane CD4 and CD8 coexpression. British Journal of Haematology, 1992, 82, 494-501.	2.5	37

#	Article	IF	Citations
37	Development and evaluation of a stabilized wholeâ€blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry. Cytometry Part B - Clinical Cytometry, 2009, 76B, 47-55.	1.5	35
38	The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Therapeutics and Clinical Risk Management, 2009, 5, 911.	2.0	33
39	Human NK Cells in Health and Disease: Clinical, Functional, Phenotypic and DNA Genotypic Characteristics. Leukemia and Lymphoma, 1992, 7, 377-399.	1.3	32
40	Immunophenotypic Dissection of Normal Peripheral Blood NK Associated (NKa) Subpopulations by Flow Cytometry: Morphological Features and Relationships Between Membrane NKa (CD11b, CD 16, CD56) Tj ETQq0 0 0 rgBT /Overlock Leukemia and Lymphoma, 1990, 2, 111-126.	1.3	28
41	Clonal CD3+CD8+ Large Granular Lymphocyte (LGL)/NK-Associated (NKa) Expansions: Primary Malignancies or Secondary Reactive Phenomena?. Leukemia and Lymphoma, 1995, 17, 303-311.	1.3	26
42	A phase 1 study to address the safety and efficacy of granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in active rheumatoid arthritis. Arthritis and Rheumatism, 1997, 40, 1838-1842.	6.7	25
43	Analysis of T Cells in Paroxysmal Nocturnal Hemoglobinuria Provides Direct Evidence That Thymic T-Cell Production Declines With Age. Blood, 1999, 94, 2790-2799.	1.4	25
44	Highâ€Sensitivity Detection of PNH Red Blood Cells, Red Cell Precursors, and White Blood Cells. Current Protocols in Cytometry, 2015, 72, 6.37.1-6.37.29.	3.7	25
45	Immunophenotypic analysis of B cells in PNH: insights into the generation of circulating naive and memory B cells. Blood, 2000, 96, 3522-3528.	1.4	24
46	The Glycosylphosphatidylinositol Anchor and Paroxysmal Nocturnal Haemoglobinuria/Aplasia Model. Acta Haematologica, 2002, 108, 219-230.	1.4	24
47	Flow cytometric analysis of membrane CD11b, CD11c and CD14 expression in acute myeloid leukaemia: relationships with monocytic subtypes and the concept of relative antigen expression. European Journal of Haematology, 1990, 44, 24-29.	2.2	24
48	The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UKâ€™s populationâ€based haematological malignancy research network 2004â€2018. European Journal of Haematology, 2021, 107, 211-218.	2.2	19
49	Concurrent treatment of aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience. Haematologica, 2018, 103, e345-e347.	3.5	18
50	Standardizing Leucocyte PNH clone detection: An international study. , 2014, , n/a-n/a.		17
51	Erythropoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria. Haematologica, 2007, 92, e31-e33.	3.5	17
52	Patterns of CD16 and CD56 expression in persistent expansions of CD3+NKa+lymphocytes are predictive for clonal T-cell receptor gene rearrangements. British Journal of Haematology, 1991, 78, 368-377.	2.5	16
53	Presentation clinical, haematological and immunophenotypic features of 1081 patients with GPIâ€deficient (paroxysmal nocturnal haemoglobinuria) cells detected by flow cytometry. British Journal of Haematology, 2020, 189, 954-966.	2.5	16
54	Improved Outcomes of Budd-Chiari Syndrome in Paroxysmal Nocturnal Hemoglobinuria with Eculizumab Therapy. Blood, 2012, 120, 3478-3478.	1.4	16

#	Article	IF	Citations
55	Persistent Clonal Expansions of CD3+TCRÎ³Î´+and CD3+TCRÎ±Î²+CD4â^'CD8â^'Lymphocytes Associated with Neutropenia. Leukemia and Lymphoma, 1994, 14, 429-440.	1.3	15
56	Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. Haematologica, 2019, 104, e94-e96.	3.5	14
57	Abnormal CD45R expression in patients with common variable immunodeficiency and X-linked agammaglobulinaemia. British Journal of Haematology, 1992, 81, 160-166.	2.5	12
58	Immunophenotypic and DNA Genotypic Analysis of T-Cell and NK-Cell Subpopulations in Patients with B-Cell Chronic Lymphocytic Leukaemia (B-CLL). Leukemia and Lymphoma, 1995, 16, 307-318.	1.3	12
59	Standardizing leucocyte PNH clone detection: An international study. , 2014, 86, 311-318.		12
60	Advances in the laboratory diagnosis of paroxysmal nocturnal hemoglobinuria. Clinical and Applied Immunology Reviews, 2001, 1, 315-330.	0.4	11
61	Immunophenotypic analysis of B cells in PNH: insights into the generation of circulating naive and memory B cells. Blood, 2000, 96, 3522-3528.	1.4	11
62	A biclonal large granular lymphocyte (LGL)/NK-associated (NKa) disorder of CD4+and CD8+lymphocyte subpopulations characterized by the simultaneous presence of distinct TCR rearrangements. British Journal of Haematology, 1994, 88, 629-632.	2.5	7
63	Immunophenotypic Analysis of PNH Cells. Current Protocols in Cytometry, 2002, 20, Unit 6.11.	3.7	7
64	Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence. Cancer Genetics and Cytogenetics, 2004, 148, 176-177.	1.0	7
65	CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria. Cytometry Part B - Clinical Cytometry, 2020, 98, 179-192.	1.5	7
66	COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria. Lancet Haematology,the, 2022, 9, e553-e556.	4.6	6
67	T-Cell Membrane CD45RA (2H4) and CD45RO (UCHL1) Determinants: I, Diverse Patterns of Expression in Mature (Post-Thymic) T-Cell Proliferations. Leukemia and Lymphoma, 1991, 4, 27-37.	1.3	5
68	Evolution of GPI-Deficient Clones Predicts Clinical Course in Paroxysmal Nocturnal Haemoglobinuria.. Blood, 2004, 104, 172-172.	1.4	5
69	Development and progression of a Philadelphia-chromosomeâ€“negative acute myelocytic leukemia clone in a patient with Philadelphia-chromosomeâ€“positive chronic myelocytic leukemia. Cancer Genetics and Cytogenetics, 2004, 148, 170-173.	1.0	4
70	Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry, 2000, 42, 223-233.	1.8	4
71	A Spontaneous Reduction of Clone Size in Paroxysmal Nocturnal Hemoglobinuria Patients Treated with Eculizumab for Greater Than 12 Months.. Blood, 2009, 114, 1992-1992.	1.4	4
72	Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy.. Blood, 2004, 104, 2823-2823.	1.4	3

#	Article	IF	Citations
73	A â€œpathogeneticâ€•role for CMV in CD4+ LGL proliferations. Blood, 2008, 112, 4367-4368.	1.4	2
74	Acquired Haemolytic Anaemias. , 2017, , 254-281.		2
75	The Effect of Eculizumab Therapy on Red Cell Response Kinetics in Patients with Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2005, 106, 1047-1047.	1.4	2
76	Patterns of Membrane Antigen Expression by AML Blasts: Quantitation and Histogram Analysis. Leukemia and Lymphoma, 1991, 5, 317-325.	1.3	1
77	Paroxysmal Nocturnal Hemoglobinuriaâ€" the Selection of a Clone. Reviews in Clinical and Experimental Hematology, 2000, 4, 216-235.	0.1	1
78	Introduction to ICCS/ESCCA Consensus Guidelines to Detect GPIâ€Deficient Cells in Paroxysmal Nocturnal Hemoglobinuria and Related Disorders. Cytometry Part B - Clinical Cytometry, 2018, 94, 12-13.	1.5	1
79	Lymphocyte Subset Analysis and Glycosylphosphatidylinositol Phenotype in Patients With Paroxysmal Nocturnal Hemoglobinuria. Blood, 1998, 92, 1799-1806.	1.4	1
80	The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood, 2000, 96, 3880-3886.	1.4	1
81	Validation of a single tube 3â€colour immature red blood cell screening assay for the detection and enumeration of small, medium and large paroxysmal nocturnal haemoglobinuria clones by flow cytometry. International Journal of Laboratory Hematology, 0, , .	1.3	1
82	T-Cell Membrane CD45RA (2H4) and CD45RO (UCHL1) Determinants: II, Aberrant HLA-ABC Expression by CD45RA and CD45RO Cell Subpopulations of Mature CD4+T-Cell Leukaemias. Leukemia and Lymphoma, 1991, 4, 39-47.	1.3	0